Summary
Global Markets Direct’s, ‘Anxiety Disorders - Pipeline Review, H1 2016’, provides an overview of the Anxiety Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Ache Laboratorios Farmaceuticos S/A
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Avineuro Pharmaceuticals, Inc.
Azevan Pharmaceuticals, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Catalyst Pharmaceutical Partners, Inc.
Edgemont Pharmaceuticals, LLC
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gabather AB
GW Pharmaceuticals Plc
HolsboerMaschmeyer NeuroChemie GmbH
Humanetics Corporation
IntelGenx Corp.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc.
Merz Pharma GmbH & Co. KgaA
MI.TO. Technology S.r.L.
Nemus Bioscience, Inc.
Neuralstem, Inc.
Neurelis, Inc.
NeuroNascent, Inc.
Newron Pharmaceuticals S.p.A.
Nippon Chemiphar Co., Ltd.
Novartis AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Polleo Pharma Limited
Protagenic Therapeutics Inc.
Suda Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
Trevena, Inc.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
Vanda Pharmaceuticals Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Anxiety Disorders Overview 11
Therapeutics Development 12
Pipeline Products for Anxiety Disorders - Overview 12
Pipeline Products for Anxiety Disorders - Comparative Analysis 13
Anxiety Disorders - Therapeutics under Development by Companies 14
Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 18
Anxiety Disorders - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Anxiety Disorders - Products under Development by Companies 23
Anxiety Disorders - Products under Investigation by Universities/Institutes 28
Anxiety Disorders - Companies Involved in Therapeutics Development 30
AbbVie Inc. 30
Ache Laboratorios Farmaceuticos S/A 31
Adamed Sp. z o.o. 32
Addex Therapeutics Ltd 33
Amorsa Therapeutics Inc. 34
Avineuro Pharmaceuticals, Inc. 35
Azevan Pharmaceuticals, Inc. 36
Bionomics Limited 37
Boehringer Ingelheim GmbH 38
C4X Discovery Holdings PLC 39
Catalyst Pharmaceutical Partners, Inc. 40
Edgemont Pharmaceuticals, LLC 41
Eisai Co., Ltd. 42
Eli Lilly and Company 43
F. Hoffmann-La Roche Ltd. 44
Gabather AB 45
GW Pharmaceuticals Plc 46
HolsboerMaschmeyer NeuroChemie GmbH 47
Humanetics Corporation 48
IntelGenx Corp. 49
Intra-Cellular Therapies, Inc. 50
INVENT Pharmaceuticals, Inc. 51
Marinus Pharmaceuticals, Inc. 52
Merz Pharma GmbH & Co. KgaA 53
MI.TO. Technology S.r.L. 54
Nemus Bioscience, Inc. 55
Neuralstem, Inc. 56
Neurelis, Inc. 57
NeuroNascent, Inc. 58
Newron Pharmaceuticals S.p.A. 59
Nippon Chemiphar Co., Ltd. 60
Novartis AG 61
Omeros Corporation 62
Otsuka Holdings Co., Ltd. 63
Pherin Pharmaceuticals, Inc. 64
Polleo Pharma Limited 65
Protagenic Therapeutics Inc. 66
Suda Ltd 67
Sumitomo Dainippon Pharma Co., Ltd. 68
Synchroneuron Inc. 69
Tonix Pharmaceuticals Holding Corp. 70
Trevena, Inc. 71
TRImaran Pharma, Inc. 72
Turing Pharmaceuticals AG 73
Vanda Pharmaceuticals Inc. 74
Anxiety Disorders - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Target 76
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
18-MC - Drug Profile 87
acamprosate calcium SR - Drug Profile 88
ACH-36 - Drug Profile 90
ADN-2013 - Drug Profile 91
ADX-71441 - Drug Profile 92
ADX-71743 - Drug Profile 94
ADX-88178 - Drug Profile 95
alprazolam - Drug Profile 97
AM-3506 - Drug Profile 98
AVN-0189 - Drug Profile 100
AVN-101 - Drug Profile 101
AVN-628 - Drug Profile 102
BNC-210 - Drug Profile 103
brexpiprazole - Drug Profile 105
CPP-115 - Drug Profile 108
D-473 - Drug Profile 110
Drug for Post-Traumatic Stress Disorders - Drug Profile 111
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 112
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 113
E-2508 - Drug Profile 114
evenamide - Drug Profile 115
fluvoxamine maleate - Drug Profile 116
Gaaba-001 - Drug Profile 117
ganaxolone - Drug Profile 118
HL-9001 - Drug Profile 120
IC-87201 - Drug Profile 121
iloperidone - Drug Profile 122
INV-107 - Drug Profile 124
INV-170 - Drug Profile 125
ITI-007 - Drug Profile 126
ketamine hydrochloride - Drug Profile 128
lorazepam - Drug Profile 129
lorazepam ER - Drug Profile 130
loxapine succinate - Drug Profile 131
LSN-2535717 - Drug Profile 132
LY-2607540 - Drug Profile 133
mavoglurant - Drug Profile 134
midazolam hydrochloride - Drug Profile 136
MRZ-8676 - Drug Profile 137
nabiximols - Drug Profile 138
NB-51R1 - Drug Profile 141
NEO-1940 - Drug Profile 142
NNI-351 - Drug Profile 143
NSI-189 - Drug Profile 144
OMS-527 - Drug Profile 146
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 148
PH-94B - Drug Profile 149
PT-00114 - Drug Profile 151
riluzole - Drug Profile 152
RO-646198 - Drug Profile 154
Rycal - Drug Profile 155
S-107 - Drug Profile 156
SCT-66 - Drug Profile 157
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 158
Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 159
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 160
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 161
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 162
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 163
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 164
Small Molecules for Obsessive-Compulsive Disorder - Drug Profile 165
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 166
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 167
Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 168
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 169
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 170
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 172
Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety - Drug Profile 173
Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression - Drug Profile 174
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 175
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 176
Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 177
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 178
Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 179
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 180
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 181
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 182
Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 183
Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile 184
SRX-246 - Drug Profile 185
STX - Drug Profile 187
TNX-102 - Drug Profile 188
TPI-136117 - Drug Profile 190
TRV-250 - Drug Profile 191
UCM-765 - Drug Profile 193
URB-694 - Drug Profile 194
Vaccine for CNS Disorders - Drug Profile 195
VAD-1 - Drug Profile 196
VAD-2 - Drug Profile 197
vigabatrin - Drug Profile 198
VU-0431316 - Drug Profile 201
VU-0456810 - Drug Profile 202
ZL-006 - Drug Profile 203
Anxiety Disorders - Recent Pipeline Updates 204
Anxiety Disorders - Dormant Projects 248
Anxiety Disorders - Discontinued Products 263
Anxiety Disorders - Product Development Milestones 269
Featured News & Press Releases 269
Appendix 277
Methodology 277
Coverage 277
Secondary Research 277
Primary Research 277
Expert Panel Validation 277
Contact Us 277
Disclaimer 278
List of Tables
Number of Products under Development for Anxiety Disorders, H1 2016 18
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Development by Companies, H1 2016 (Contd..1) 21
Number of Products under Development by Companies, H1 2016 (Contd..2) 22
Number of Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Late Stage Development, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Development, H1 2016 27
Comparative Analysis by Unknown Stage Development, H1 2016 28
Products under Development by Companies, H1 2016 29
Products under Development by Companies, H1 2016 (Contd..1) 30
Products under Development by Companies, H1 2016 (Contd..2) 31
Products under Development by Companies, H1 2016 (Contd..3) 32
Products under Development by Companies, H1 2016 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2016 34
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 35
Anxiety Disorders - Pipeline by AbbVie Inc., H1 2016 36
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 37
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H1 2016 38
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H1 2016 39
Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H1 2016 40
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 41
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 42
Anxiety Disorders - Pipeline by Bionomics Limited, H1 2016 43
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H1 2016 44
Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H1 2016 45
Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 46
Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2016 47
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H1 2016 48
Anxiety Disorders - Pipeline by Eli Lilly and Company, H1 2016 49
Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50
Anxiety Disorders - Pipeline by Gabather AB, H1 2016 51
Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H1 2016 52
Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016 53
Anxiety Disorders - Pipeline by Humanetics Corporation, H1 2016 54
Anxiety Disorders - Pipeline by IntelGenx Corp., H1 2016 55
Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 56
Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 57
Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 58
Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 59
Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H1 2016 60
Anxiety Disorders - Pipeline by Nemus Bioscience, Inc., H1 2016 61
Anxiety Disorders - Pipeline by Neuralstem, Inc., H1 2016 62
Anxiety Disorders - Pipeline by Neurelis, Inc., H1 2016 63
Anxiety Disorders - Pipeline by NeuroNascent, Inc., H1 2016 64
Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 65
Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 66
Anxiety Disorders - Pipeline by Novartis AG, H1 2016 67
Anxiety Disorders - Pipeline by Omeros Corporation, H1 2016 68
Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 69
Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 70
Anxiety Disorders - Pipeline by Polleo Pharma Limited, H1 2016 71
Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H1 2016 72
Anxiety Disorders - Pipeline by Suda Ltd, H1 2016 73
Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 74
Anxiety Disorders - Pipeline by Synchroneuron Inc., H1 2016 75
Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 76
Anxiety Disorders - Pipeline by Trevena, Inc., H1 2016 77
Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H1 2016 78
Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H1 2016 79
Anxiety Disorders - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 80
Assessment by Monotherapy Products, H1 2016 81
Number of Products by Stage and Target, H1 2016 83
Number of Products by Stage and Mechanism of Action, H1 2016 87
Number of Products by Stage and Route of Administration, H1 2016 90
Number of Products by Stage and Molecule Type, H1 2016 92
Anxiety Disorders Therapeutics - Recent Pipeline Updates, H1 2016 210
Anxiety Disorders - Dormant Projects, H1 2016 254
Anxiety Disorders - Dormant Projects (Contd..1), H1 2016 255
Anxiety Disorders - Dormant Projects (Contd..2), H1 2016 256
Anxiety Disorders - Dormant Projects (Contd..3), H1 2016 257
Anxiety Disorders - Dormant Projects (Contd..4), H1 2016 258
Anxiety Disorders - Dormant Projects (Contd..5), H1 2016 259
Anxiety Disorders - Dormant Projects (Contd..6), H1 2016 260
Anxiety Disorders - Dormant Projects (Contd..7), H1 2016 261
Anxiety Disorders - Dormant Projects (Contd..8), H1 2016 262
Anxiety Disorders - Dormant Projects (Contd..9), H1 2016 263
Anxiety Disorders - Dormant Projects (Contd..10), H1 2016 264
Anxiety Disorders - Dormant Projects (Contd..11), H1 2016 265
Anxiety Disorders - Dormant Projects (Contd..12), H1 2016 266
Anxiety Disorders - Dormant Projects (Contd..13), H1 2016 267
Anxiety Disorders - Dormant Projects (Contd..14), H1 2016 268
Anxiety Disorders - Discontinued Products, H1 2016 269
Anxiety Disorders - Discontinued Products (Contd..1), H1 2016 270
Anxiety Disorders - Discontinued Products (Contd..2), H1 2016 271
Anxiety Disorders - Discontinued Products (Contd..3), H1 2016 272
Anxiety Disorders - Discontinued Products (Contd..4), H1 2016 273
Anxiety Disorders - Discontinued Products (Contd..5), H1 2016 274
List of Figures
Number of Products under Development for Anxiety Disorders, H1 2016 18
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Products, H1 2016 27
Assessment by Monotherapy Products, H1 2016 81
Number of Products by Top 10 Targets, H1 2016 82
Number of Products by Stage and Top 10 Targets, H1 2016 82
Number of Products by Top 10 Mechanism of Actions, H1 2016 86
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 86
Number of Products by Routes of Administration, H1 2016 89
Number of Products by Stage and Routes of Administration, H1 2016 89
Number of Products by Molecule Types, H1 2016 91
Number of Products by Stage and Molecule Types, H1 2016 91
